Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02401815 · ClinicalTrials.gov registry record · Phase 1
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Cogent Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02401815 is a Phase 1 study that has completed, run by Cogent Biosciences. The registered enrollment target is 51 participants.
The verdict
NCT02401815, a Phase 1 study, has completed, sponsored by Cogent Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect cancer cells with certain mutations in the KIT gene, specifically in participants with types of advanced solid tumors including gastrointestinal stromal tumor (GIST). CGT9486 (fka PLX9486) is designed to block KIT gene mutations. These mutations can cause cancer and cancer cell growth. By blocking these mutations, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing. By combining CGT9486 (fka PLX9486) with PLX3397 and CGT9486 (fka PLX9486) with sunitinib, the investigators hope to block most KIT gene mutations that drive cancer growth.
Interventions
- DRUG Sunitinib
- DRUG CGT9486
- DRUG Pexidartinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-03-06 |
| Est. Completion | 2020-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02401815
The ClinicalTrials.gov registry entry for NCT02401815 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sunitinib is the first listed.
NCT02401815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02401815 about?
NCT02401815 is a clinical study titled "CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors". The goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect cancer cells with certain mutations in the KIT gene, specifically in participants with types of advanced solid tumors including gastrointestinal stromal tumor (GIST). CGT9486 (fka PLX9486) is designed to block...
What is the current status of trial NCT02401815?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-03-06. Estimated completion is 2020-05-11.
What interventions are being tested in trial NCT02401815?
The interventions under investigation include: Sunitinib (DRUG), CGT9486 (DRUG), Pexidartinib (DRUG).
Who is sponsoring clinical trial NCT02401815?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.